Literature DB >> 30578385

The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study.

Sebastiano Emanuele Torrisi1, Brett Ley2, Michael Kreuter3, Marlies Wijsenbeek4, Eric Vittinghoff5, Harold R Collard2, Carlo Vancheri1.   

Abstract

BACKGROUND: The gender-age-physiology (GAP) model was developed to predict the risk of death. Comorbidities are common in idiopathic pulmonary fibrosis (IPF) and may impact on survival. We evaluated the ability of comorbidities to improve prediction of survival in IPF patients beyond the variables included in the GAP model.
METHODS: We developed a prediction model named TORVAN using data from two independent cohorts. Continuous and point-score prediction models were developed with estimation of full and sparse versions of both. Model discrimination was assessed using the C-index and calibrated by comparing predicted and observed cumulative mortality at 1-5 years.
RESULTS: Discrimination was similar for the sparse continuous model in the derivation and validation cohorts (C-index 71.0 versus 70.0, respectively), and significantly improved the performance of the GAP model in the validation cohort (increase in C-index of 3.8, p=0.001). In contrast, the sparse point-score model did not perform as well in the validation cohort (C-index 72.5 in the derivation cohort versus 68.1 in the validation cohort), but still significantly improved upon the performance of the GAP model (C-index increased by 2.5, p=0.037).
CONCLUSIONS: The inclusion of comorbidities in TORVAN models significantly improved the discriminative performance in prediction of risk of death compared to GAP.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 30578385     DOI: 10.1183/13993003.01587-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

1.  The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities.

Authors:  Antonella Caminati; Fabiana Madotto; Sara Conti; Giancarlo Cesana; Lorenzo Mantovani; Sergio Harari
Journal:  Intern Emerg Med       Date:  2021-02-14       Impact factor: 3.397

2.  Accuracy and complications of percutaneous transthoracic needle lung biopsy for the diagnosis of malignancy in patients with idiopathic pulmonary fibrosis.

Authors:  Yoon Joo Shin; Gabin Yun; Sung Hyun Yoon; Hwayoung Song; Junghoon Kim; Jihang Kim; Jong Sun Park; Kyoung Won Lee; Kyung Hee Lee
Journal:  Eur Radiol       Date:  2021-05-18       Impact factor: 5.315

3.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Authors:  Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos
Journal:  J Heart Lung Transplant       Date:  2021-07-24       Impact factor: 13.569

4.  Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.

Authors:  Dragana M Jovanovic; Martina Šterclová; Nesrin Mogulkoc; Katarzyna Lewandowska; Veronika Müller; Marta Hájková; Michael Studnicka; Jasna Tekavec-Trkanjec; Simona Littnerová; Martina Vašáková
Journal:  Respir Res       Date:  2022-05-27

5.  Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome.

Authors:  Jaume Bordas-Martínez; Ricard Gavaldà; Jessica G Shull; Vanesa Vicens-Zygmunt; Lurdes Planas-Cerezales; Guadalupe Bermudo-Peloche; Salud Santos; Neus Salord; Carmen Monasterio; Maria Molina-Molina; Guillermo Suarez-Cuartin
Journal:  ERJ Open Res       Date:  2021-05-10

Review 6.  Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.

Authors:  Paola Faverio; Marialuisa Bocchino; Antonella Caminati; Alessia Fumagalli; Monica Gasbarra; Paola Iovino; Alessandra Petruzzi; Luca Scalfi; Alfredo Sebastiani; Anna Agnese Stanziola; Alessandro Sanduzzi
Journal:  Nutrients       Date:  2020-04-17       Impact factor: 5.717

7.  Risk assessment in interstitial lung disease: the incremental prognostic value of cardiopulmonary ultrasound.

Authors:  Wei-Wei Zhu; Hong Li; Yi-Dan Li; Lanlan Sun; Lingyun Kong; Xiaoguang Ye; Qizhe Cai; Xiu-Zhang Lv
Journal:  BMC Pulm Med       Date:  2021-07-15       Impact factor: 3.317

8.  Comorbidities of Patients With Idiopathic Pulmonary Fibrosis in Four Latin American Countries. Are There Differences by Country and Altitude?

Authors:  Mauricio Gonzalez-Garcia; Emily Rincon-Alvarez; Maria Laura Alberti; Mauricio Duran; Fabian Caro; Maria Del Carmen Venero; Yuri Edison Liberato; Ivette Buendia-Roldan
Journal:  Front Med (Lausanne)       Date:  2021-06-17

9.  The Value of the Surprise Question to Predict One-Year Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study.

Authors:  Catharina C Moor; Nelleke C Tak van Jaarsveld; Catherine Owusuaa; Jelle R Miedema; Sara Baart; Carin C D van der Rijt; Marlies S Wijsenbeek
Journal:  Respiration       Date:  2021-05-27       Impact factor: 3.580

10.  Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.

Authors:  Sebastiano Emanuele Torrisi; Nicolas Kahn; Julia Wälscher; Nilab Sarmand; Markus Polke; Kehler Lars; Monika Eichinger; Claus Peter Heussel; Stefano Palmucci; Francesca Maria Sambataro; Gianluca Sambataro; Domenico Sambataro; Carlo Vancheri; Michael Kreuter
Journal:  BMC Pulm Med       Date:  2019-11-12       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.